In 2012, the audit of government programs that affect the pharmaceutical
market took place. In the previous year, a number of laws were approved. It will
affect the development of the market in the short and long term (for example,
increasing the availability of high-quality, effective and safe medicines to meet
needs of the population is the main goal of "The Strategy of providing the
population of the Russian Federation with drugs till 2025".
The Russian pharmaceutical market is among the ten largest pharmaceutical
markets in the world. At the end of 2012 Russia took the 7th place. In Russia in
2012, the value of the pharmaceutical market amounted to 921 billion rubles (VAT)
in consumer prices, which is 12% more compared to 2011. Russia was ranked third
for growth rate.
The Russian pharmaceutical market is import oriented. 76% of drugs in
terms of money consumed by the population are produced abroad. Therefore, on
the first place in the ranking of foreign producers is: SANOFI, NOVARTIS. On the
third line is PHARMSTANDARD - the only domestic manufacture of the top 20
leading players in the Russian pharmaceutical market.
The development of the pharmaceutical distribution sector of the market is on a
given vector in recent years - business diversification: all national distributors are
within the control structure of a subordinate pharmacy chains, the second direction,
which is actively developing – is domestic manufacture. In 2012, there was a
redistribution of the market. "Protek" took the leading position with a share of
16.5%. "Sensation" of the year – the distributor "Katren" got the second place.
Rounding up the Top-3 was the distributor "SIA" (Leader of previous years). Their
combined share of the total market is 44%.
For the pharmacy chain, the year was marked by the development of new
formats within the chain. Many market players have discount stores under different
brand names now. On the other hand pharmacy chains offer premium pharmacies,
shops and cosmetic studios, etc. Also redistribution of the market take place in the
retail segment - the leader of the pharmacy chain is "Rigla", "A5" takes the second
